| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 1.76 Billion | USD 5.08 Billion | 11.20% | 2024 |
FrequentlyAsked Questions
Sacral neuromodulation is an advanced medical therapy that uses electrical stimulation to treat pelvic floor disorders and chronic pain. This minimally invasive procedure involves implanting a small device that sends controlled electrical pulses to the sacral nerves, restoring normal nerve function and alleviating symptoms.
The sacral neuromodulation market is expected to be driven by increasing prevalence of pelvic floor disorders, rising aging population, growing awareness of minimally invasive treatments, expanding clinical evidence supporting neuromodulation therapies, and technological advancements in device design.
According to our study, the global sacral neuromodulation market was worth around USD 1.76 billion in 2024 and is predicted to grow to around USD 5.08 billion by 2034.
The CAGR value of the sacral neuromodulation market is expected to be around 11.20% during 2025-2034.
The global sacral neuromodulation market will register the highest revenue contribution from North America during the forecast period.
Key players in the sacral neuromodulation market include Medtronic plc, Boston Scientific Corporation, Axonics Modulation Technologies Inc., Abbott Laboratories, Nevro Corporation, LivaNova PLC, Cyberonics Inc., Nuvectra Corporation, St. Jude Medical Inc., Cochlear Limited, Sonova Holding AG, MED-EL Elektromedizinische Geräte GmbH, Advanced Bionics LLC, Neuronetics Inc., and Magstim Company Ltd.
The report provides a comprehensive analysis of the sacral neuromodulation market, including an in-depth examination of market drivers, restraints, emerging trends, regional dynamics, and future growth prospects. It also examines the competitive dynamics, technological innovations, distribution strategies, and clinical practices that shape the modern medical devices ecosystem.
HappyClients